Litigation Details for Novartis Pharma AG v. Incyte Corporation (S.D.N.Y. 2020)

✉ Email this page to a colleague

Docket	⤷ Try a Trial	Date Filed	2020-01-15
Court	District Court, S.D. New York	Date Terminated
Cause	28:1332bc Diversity-Breach of Contract	Assigned To	Gregory Howard Woods III
Jury Demand		Referred To	Gabriel W. Gorenstein
Patents	10,016,429; 7,598,257; 8,415,362; 8,722,693; 8,822,481; 8,829,013; 9,079,912; 9,814,722
Link to Docket	External link to docket

The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .

Subscribe to access the full database, or Try a Trial
Date Filed	Document No.	Description	Snippet	Link To Document
2020-04-30	35	Memorandum of Law in Support of Motion	8,822,481, 8,829,013, 9,079,912, 9,814,722, and 10,016,429. Compl. ¶ 26. The U.S. P.T.O.’s website’s records…and domestic patents under “Incyte Patent Rights,” there is no such list of Novartis patents appended. …Notably, the terms “Patent Rights,” “Incyte Patent Rights,” and “Novartis Patent Rights” were separately…that each of those patents is a U.S. patent owned by Incyte.6 Because Incyte patents are irrelevant under…definition; it defines “Patent Rights” as encompassing “all patents and patent applications.” Sections	External link to document
2021-03-23	63	Answer to Complaint	Incyte further admits Incyte’s United States Patent No. 7,598,257 was submitted to the FDA’s Orange Book …Incyte admits certain United States patents cover Jakafi, those patents were all invented and developed by…applicable Novartis United States patents and so there are no Licensed Patent Rights Covering ruxolitinib …discoveries and obtain relevant patents—that is, develop Licensed Patent Rights Covering …infringe a patent absent a license—and Incyte’s sales obviously can not infringe Incyte’s own patents. In	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document